Use of oxandrolone in the treatment of burns and other wounds

• US 20020165266A1
• Filed: 10/22/2001
• Published: 11/07/2002
• Est. Priority Date: 12/05/1996
• Status: Active Grant

• Current Assignee: Gemini Laboratories, LLC
• Original Assignee: Bio-Technology General Corp.
• Inventors: Fishbein, Don
• Granted Patent: US 6,828,313 B2
• Time in Patent Office: Days
• US Class Current: 514/453
• CPC Class Codes: A61K 31/366 having six-membered rings, e.g. delta-lactones
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00

Abstract

The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.

Claims

1. A method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient.

3. A method according to claims 1 or 2, wherein the wound is a burn wound.

4. A method according to claims 1 or 2, wherein the wound comprises an ulcer.

5. A method according to claims 1 or 2, wherein the wound comprises a skin graft.

6. A method according to claims 1 or 2 wherein the amount of the oxandrolone is about 1-100 mg per day.

7. A method according to claim 6 wherein the amount of the oxandrolone is about 20 mg per day.

8. A method according to claim 6 wherein the amount of the oxandrolone is about 80 mg per day.

9. A method according to claims 1 or 2 wherein the oxandrolone is administered orally.

10. A method according to claims 1 or 2 wherein the oxandrolone is administered topically.

11. A method according to claims 1 or 2 wherein the oxandrolone is injected.

12. A method according to claims 1 or 2 wherein the oxandrolone is in a solid dosage form.

13. A method according to claims 1 or 2 wherein the oxandrolone is in a liquid dosage form.

14. A method according to claims 1 or 2 wherein the oxandrolone is in a sustained-release formulation.

18. A method according to claim 17 wherein the amount of the oxandrolone is about 20 mg per day.

19. A method according to claim 17 wherein the amount of the oxandrolone is about 80 mg per day.

28. A method according to claims 1, 2, 15 or 16, wherein the oxandrolone is 17α

-methyl-17β

-hydroxy-2-oxa-5α

-androstan-3-one.

29. A method according to claim 4 wherein the ulcer is a decubitus ulcer.

2. A method of improving the rate of healing of a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient.

15. A method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient.

17. A method according to claims 15 or 16 wherein the amount of the oxandrolone is about 1-100 mg per day.

20. A method according to claims 15 or 16 wherein the oxandrolone is administered orally.

21. A method according to claims 15 or 16 wherein the oxandrolone is administered topically.

22. A method according to claims 15 or 16 wherein the oxandrolone is injected.

23. A method according to claims 15 or 16 wherein the oxandrolone is in a solid dosage form.

24. A method according to claims 15 or 16 wherein the oxandrolone is in a liquid dosage form.

25. A method according to claims 15 or 16 wherein the oxandrolone is in a sustained-release formulation.

27. A composition according to claim 26 wherein the wound is selected from the group consisting of a burn, an ulcer and a skin graft.

16. A method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.

26. A composition for use in topical treatment of wounds which comprises an oxandrolone and a pharmaceutically acceptable carrier.